Diabetes and the platelet: Toward new therapeutic paradigms for diabetic atherothrombosis

Atherosclerosis

Volumn 212, Issue 2, 2010, Pages 367-376

  Morel, Olivier ^a,b,c   Kessler, Laurence ^b   Ohlmann, Patrick ^a   Bareiss, Pierre ^a  

^a HÔPITAL CIVIL   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c Dept Environ Med Natl Inst Publ HIth   (Norway)

Author keywords

Acute coronary syndrome; Apoptosis; Microparticles; Plaque; Platelet; Statins; Thienopyridines; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; ASCORBIC ACID; CILOSTAZOL; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; INSULIN; PITAVASTATIN; PLACEBO; PRASUGREL; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; THIENOPYRIDINE DERIVATIVE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC ATHEROTHROMBOSIS; DIABETIC PATIENT; DIABETIC RETINOPATHY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG INHIBITION; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; GLYCEMIC CONTROL; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PLATELET MICROPARTICLE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; STROKE; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOGENESIS; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; APOPTOSIS; ASPIRIN; BLOOD PLATELETS; DIABETES COMPLICATIONS; DIABETES MELLITUS; GLYCOPROTEINS; HUMANS; MODELS, BIOLOGICAL; PIPERAZINES; PLATELET ACTIVATION; RECEPTORS, PURINERGIC P2Y12; THIOPHENES; THROMBOPLASTIN; THROMBOSIS; TICLOPIDINE;

EID: 77956379970     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.03.019     Document Type: Review

References (90)

1. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
2. Coccheri S. Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drugs 2007, 67:997-1026.
3. Wilson G., Perry T. Is tight glycemic control in type 2 diabetes really worthwhile? No. Can Fam Physician 2009, 55:581.
4. American Diabetes Association Implications of the diabetes control and complications trial. Diabetes Care 2003, 26:S25-S27.
5. American Diabetes Association Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 2000, 23:S27-S31.
6. Koga H., Sugiyama S., Kugiyama K., et al. Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2005, 45:1622-1630.
7. Morel O., Hugel B., Jesel L., et al. Sustained elevated amounts of circulating procoagulant membrane microparticles and soluble GPV after acute myocardial infarction in diabetes mellitus. Thromb Haemost 2004, 91:345-353.
8. Kessler L., Wiesel M.L., Attali P., Mossard J.M., Cazenave J.P., Von Pinget M. Willebrand factor in diabetic angiopathy. Diabetes Metab 1998, 24:327-336.
9. Boden G., Rao A.K. Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation. Curr Diab Rep 2007, 7:223-227.
10. Angiolillo D.J. Antiplatelet therapy in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2007, 14:124-131.
11. Arjomand H., Roukoz B., Surabhi S.K., Cohen M. Platelets and antiplatelet therapy in patients with diabetes mellitus. J Invas Cardiol 2003, 15:264-269.
12. Yamagishi S., Nakamura K., Imaizumi T. Advanced glycation end products (AGEs) and diabetic vascular complications. Curr Diabetes Rev 2005, 1:93-106.
13. Chappey O., Dosquet C., Wautier M.P., Wautier J.L. Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest 1997, 27:97-108.
14. Beckman J.A., Creager M.A., Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002, 287:2570-2581.
15. Thomas G., Skrinska V., Lucas F.V., Schumacher O.P. Platelet glutathione and thromboxane synthesis in diabetes. Diabetes 1985, 34:951-954.
16. Davì G., Catalano I., Averna M., et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990, 322:1769-1774.
17. Queen L.R., Ji Y., Goubareva I., Ferro A. Nitric oxide generation mediated by β-adrenoceptors is impaired in platelets from patients with Type 2 diabetes mellitus. Diabetologia 2003, 46:1474-1482.
18. 2+ hemostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol 2001, 280:1480H-1489H.
19. Cattaneo M. ADP receptors: inhibitory strategies for antiplatelet therapy. Drug News Perspect 2006, 19:253-259.
20. Matsuno H., Tokuda H., Ishisaki A., Zhou Y., Kitajima Y., Kozawa O. P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes. J Clin Endocrinol Metab 2005, 90:920-927.
21. Burnier L., Fontana P., Kwak B.R., Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 2009, 101:439-451.
22. George F.D. Microparticles in vascular diseases. Thromb Res 2008, 122:S55-S59.
23. Morel O., Morel N., Freyssinet J.M., Toti F. Platelet microparticles and vascular cells interactions: a checkpoint between the haemostatic and thrombotic responses. Platelets 2008, 19:2-9.
24. Schwertz H., Tolley N.D., Foulks J.M., et al. Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets. J Exp Med 2006, 203:2433-2440.
25. Leroyer A.S., Tedgui A., Boulanger C.M. Role of microparticles in atherothrombosis. J Intern Med 2008, 263:528-537.
26. Ardoin S.P., Shanahan J.C., Pisetsky D.S. The role of microparticles in inflammation and thrombosis. Scand J Immunol 2007, 66:159-165.
27. Nomura S., Suzuki M., Katsura K., et al. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis 1995, 116:235-240.
28. Diamant M., Nieuwland R., Pablo R.F., Sturk A., Smit J.W., Radder J.K. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002, 106:2442-2447.
29. Ueba T., Haze T., Sugiyama M., et al. Level, distribution and correlates of platelet-derived microparticles in healthy individuals with special reference to the metabolic syndrome. Thromb Haemost 2008, 100:280-285.
30. Scheen A.J., Legrand D. Aspirin and clopidogrel resistance in patients with diabetes mellitus. Eur Heart J 2006, 27:2900.
31. Singla A., Antonino M.J., Bliden K.P., Tantry U.S., Gurbel P.A. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. Am Heart J 2009, 158:784.e1-784.e6.
32. Evangelista V., Totani L., Rotondo S., et al. Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin. Thromb Haemost 2005, 93:8-16.
33. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005, 54:2430-2435.
34. Bhatt D.L., Fox K.A.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006, 354:1706-1717.
35. Angiolillo D.J., Capranzano P., Goto S., et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J 2008, 29:2202-2211.
36. Yang T.H., Kim D.I., Kim J.Y., et al. Comparison of triple anti-platelet therapy (aspirin, clopidogrel, and cilostazol) and double anti-platelet therapy (aspirin and clopidogrel) on platelet aggregation in type 2 diabetic patients undergoing drug-eluting stent implantation. Kor Circ J 2009, 39(November):462-466.
37. Jeong Y.H., Lee S.W., Choi B.R., et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009, 53:1101-1109.
38. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989, 321:129-135. Steering Committee of the Physicians' Health Study Research Group.
39. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755-1762.
40. Sacco M., Pellegrini F., Roncaglioni M.C., et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients. Results of the Primary Prevention Project trial. Diabetes Care 2003, 26:3264-3272.
41. Angiolillo D.J., Suryadevara S. Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. Best Pract Res Clin Endocrinol Metab 2009, 23:375-388.
42. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14. ETDRS Investigators. JAMA 1992, 268:1292-1300.
43. Belch J., MacCuish A., Campbell I., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008, 337:a1840.
44. Ogawa H., Nakayama M., Morimoto T., et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008, 300:2134-2141.
45. Wang T.H., Bhatt D.L., Fox K.A., et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J 2007, 28:2200-2207.
46. Hayden M.R., Tyagi S.C. Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformation. Cardiovasc Diabetol 2004, 3:1.
47. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996, 348:1329-1339.
48. Bhatt D.L., Marso S.P., Hirsch A.T., et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002, 90:625-628.
49. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
50. Mehran R., Dangas G.D., Kobayashi Y., et al. Short- and long-term results after multivessel stenting in diabetic patients. J Am Coll Cardiol 2004, 43:1348-1354.
51. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007, 369:667-678.
52. Bhatt D.L., Marso S.P., Lincoff A.M., Wolski K.E., Ellis S.G., Topol E.J. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000, 35:922-928.
53. Mehilli J., Kastrati A., Schühlen H., et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004, 110:3627-3635.
54. Talarico G.P., Brancati M., Burzotta F., et al. Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study. J Cardiovasc Med (Hagerstown) 2009, 10:245-251.
55. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358:527-533.
56. Wiviott S.D., Braunwald E., Angiolillo D.J., et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008, 118:1626-1636.
57. Han Y., Li Y., Wang S., et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009, 157:733-739.
58. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006, 55:780-784.
59. Morel O., Toti F., Hugel B., et al. Procoagulant microparticles: disrupting the vascular homeostasis equation?. Arterioscler Thromb Vasc Biol 2006, 26:2594-2604.
60. Gross P.L., Furie B.C., Merrill-Skoloff G., Chou J., Furie B. Leukocyte-versus microparticle-mediated tissue factor transfer during arteriolar thrombus development. J Leukoc Biol 2005, 78:1318-1326.
61. Thomas G.M., Panicot-Dubois L., Lacroix R., Dignat-George F., Lombardo D., Dubois C. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med 2009, 206:1913-1927.
62. Hrachovinová I., Cambien B., Hafezi-Moghadam A., et al. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med 2003, 9:1020-1025.
63. Chou J., Mackman N., Merrill-Skoloff G., Pedersen B., Furie B.C., Furie B. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 2004, 104:3190-3197.
64. Ramacciotti E., Hawley A.E., Farris D.M., et al. Leukocyte- and platelet-derived microparticles correlate with thrombus weight and tissue factor activity in an experimental mouse model of venous thrombosis. Thromb Haemost 2009, 101:748-754.
65. Bogdanov V.Y., Osterud B. Cardiovascular complications of diabetes mellitus: the tissue factor perspective. Thromb Res 2010, 125:112-118.
66. Khechai F., Ollivier V., Bridey F., Amar M., Hakim J., de Prost D. Effect of advanced glycation end product-modified albumin on tissue factor expression by monocytes. Role of oxidant stress and protein tyrosine kinase activation. Arterioscler Thromb Vasc Biol 1997, 17:2885-2890.
67. Ichikawa K., Yoshinari M., Iwase M., et al. Advanced glycosylation end products induced tissue factor expression in human monocyte-like U937 cells and increased tissue factor expression in monocytes from diabetic patients. Atherosclerosis 1998, 136:281-287.
68. Vaidyula V.R., Boden G., Rao A.K. Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets 2006, 17:577-585.
69. Sabatier F., Darmon P., Hugel B., et al. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes 2002, 51:2840-2845.
70. Johansson H., Lukinius A., Moberg L., et al. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 2005, 54:1755-1762.
71. Ettelaie C., Su S., Li C., Collier M.E. Tissue factor-containing microparticles released from mesangial cells in response to high glucose and AGE induce tube formation in microvascular cells. Microvasc Res 2008, 76:152-160.
72. Nomura S., Inami N., Shouzu A., Urase F., Maeda Y. Correlation and association between plasma platelet-, monocyte- and endothelial cell-derived microparticles in hypertensive patients with type 2 diabetes mellitus. Platelets 2009, 20:406-414.
73. Kang L., Chen Q., Wang L., et al. Decreased mobilization of endothelial progenitor cells contributes to impaired neovascularization in diabetes. Clin Exp Pharmacol Physiol 2009, 36:e47-e56.
74. Pirro M., Schillaci G., Bagaglia F., et al. Microparticles derived from endothelial progenitor cells in patients at different cardiovascular risk. Atherosclerosis 2008, 197:757-767.
75. Feng B., Chen Y., Luo Y., Chen M., Li X., Ni Y. Circulating level of microparticles and their correlation with arterial elasticity and endothelium-dependent dilation in patients with type 2 diabetes mellitus. Atherosclerosis 2009, 10.1016/j.atherosclerosis.2009.06.037.
76. Bernard S., Loffroy R., Sérusclat A., et al. Increased levels of endothelial microparticles CD144 (VE-Cadherin) positives in type 2 diabetic patients with coronary noncalcified plaques evaluated by multidetector computed tomography (MDCT). Atherosclerosis 2009, 203:429-435.
77. Nozaki T., Sugiyama S., Koga H., et al. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. J Am Coll Cardiol 2009, 54:601-608.
78. Leroyer A.S., Tedgui A., Boulanger C.M. Microparticles and type 2 diabetes. Diabetes Metab 2008, 34:S27-32.
79. Tabas I., Seimon T., Arellano J., et al. The impact of insulin resistance on macrophage death pathways in advanced atherosclerosis. Novartis Found Symp 2007, 286:99-109.
80. Bonderman D., Teml A., Jakowitsch J., et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 2002, 99:2794-2800.
81. Morel O., Pereira B., Averous G., et al. Increased levels of procoagulant tissue factor-bearing microparticles within the occluded coronary artery of patients with ST-segment elevation myocardial infarction: role of endothelial damage and leukocyte activation. Atherosclerosis 2009, 204:636-641.
82. Steppich B.A., Braun S.L., Stein A., et al. Plasma TF activity predicts cardiovascular mortality in patients with acute myocardial infarction. Thromb J 2009, 7:11.
83. Gerrits A.J., Koekman C.A., Yildirim C., Nieuwland R., Akkerman J.W. Insulin inhibits tissue factor expression in monocytes. J Thromb Haemost 2009, 7:198-205.
84. Tramontano A.F., O'Leary J., Black A.D., Muniyappa R., Cutaia M.V., El-Sherif N. Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the Rho-kinase pathway. Biochem Biophys Res Commun 2004, 320:34-38.
85. Sommeijer D.W., Joop K., Leyte A., Reitsma P.H., ten Cate H. Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes. J Thromb Haemost 2005, 3:1168-1171.
86. Nomura S., Inami N., Shouzu A., et al. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. Platelets 2009, 20:16-22.
87. Koh K.K., Quon M.J., Han S.H., Ahn J.Y., Lee Y., Shin E.K. Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes. Atherosclerosis 2007, 194:230-237.
88. Diamant M., Tushuizen M.E., Abid-Hussein M.N., et al. Simvastatin-induced endothelial cell detachment and microparticle release are prenylation dependent. Thromb Haemost 2008, 100:489-497.
89. Morel O., Jesel L., Hugel B., et al. Protective effects of vitamin C on endothelium damage and platelet activation during myocardial infarction in patients with sustained generation of circulating microparticles. J Thromb Haemost 2003, 1:171-177.
90. Nomura S., Shouzu A., Taomoto K., et al. Assessment of an ELISA kit for platelet-derived microparticles by joint research at many institutes in Japan. J Atheroscler Thromb 2009, JST.JSTAGE/jat/2642.